TRUNKIERTES HBC CORE-PROTEIN PLUS EIN SAPONIN- BASIERENDES ADJUVANS ENTHALTENDE VAKZINE

Composition (A) comprises (i) one or more hepatitis B core antigens (HBcAg) containing amino acids 1 to x (x = 100-160),their fragments, variants of fragment variants; (ii) an adjuvant containing a saponin and/or saponin derivative; and (iii) optionally, one or more hepatitis B surface antigens (HBs...

Full description

Saved in:
Bibliographic Details
Main Authors JANOWICZ, ZBIGNIEW, BUCHMANN, PASCALE, MELBER, KARL
Format Patent
LanguageGerman
Published 15.05.2012
Online AccessGet full text

Cover

More Information
Summary:Composition (A) comprises (i) one or more hepatitis B core antigens (HBcAg) containing amino acids 1 to x (x = 100-160),their fragments, variants of fragment variants; (ii) an adjuvant containing a saponin and/or saponin derivative; and (iii) optionally, one or more hepatitis B surface antigens (HBsAg), or their fragments, variants or variant fragments. ACTIVITY : Virucide; Hepatotropic; Antiinflammatory. Mice were immunized with a composition containing 5 mu g AbISCO-200 (RTM for a saponin composition) and 10 mu g HBcAg1-144+1 in 0.1 ml phosphate-buffered saline. The number of CD8 +> cells that expressed gamma -interferon was just over 100 per 10 5> such cells; compared with zero when the same antigen was administered without saponin. When the composition also contained 5 mu g HBsAg, the number of such cells was 170/10 5>. The composition also resulted in high levels of immunoglobulins G1 and G2b, indicating a Th1/Th2 response. MECHANISM OF ACTION : Vaccine.
Bibliography:Application Number: AT20060792095T